| PU25.03 | Health care providers' preferences about an MPT implant: insights from South Africa and Zimbabwe on the Subcutaneous Contraceptive HIV Implant Engineered for Long-acting Delivery (SCHIELD) Study | Publication Only | Product acceptability and adherence |
| PU26.01 | Quality and turnaround times of PMTCT viral load monitoring under Option B+ in six South African districts with high antenatal HIV burden | Publication Only | Testing: technology, coverage, viral load, point of care and CD4 count |
| PU28.01 | Findings from an HIV risk behavior assessment among penal and probation population in Ukraine | Publication Only | Therapeutic vaccines, viral reservoirs and eradication/remission |
| PU28.02 | Factors associated with knowledge of PEP and PrEP among female sex workers in 12 Brazilian cities | Publication Only | Transmission of HIV |
| PU28.03 | Partner age-disparity, sexual risk, and geographic mobility in rural Kenyan and Ugandan communities | Publication Only | Transmission of HIV |
| PU29.01 | Programming for female sex workers during COVID-19 pandemic: experiences from Bar Hostess Empowerment and Support Program, Nairobi Kenya | Publication Only | Treatment as prevention |
| HY01.01LB | VRC01 antibody prevention of HIV | Oral Abstract Session | Clinical trial results |
| HY01.02LB | Long acting injectable cabotegravir is safe and effective in preventing HIV infection in cisgender women: interim results from HPTN 084 | Oral Abstract Session | Clinical trial results |
| OA01.01 | Evaluation of the kinetics of systemic distribution of IV injected monoclonal antibodies modified to alter host mediated Fc interaction in the rhesus macaque model | Oral Abstract Session | Broadly neutralizing antibodies |
| OA01.02 | Monoclonal antibodies with ultra-long CDRH3 derived from vaccinated cows show exceptional neutralisation potency and breadth that is retained after Fc engineering | Oral Abstract Session | Humoral immunity |